共 21 条
[1]
Bianchini G(2016)Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Nat Rev Clin Oncol 13 674-690
[2]
Larkin J(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34
[3]
Rizvi NA(2015)Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348 124-128
[4]
Ferris RL(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck N Engl J Med 375 1856-1867
[5]
Schmid P(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med 379 2108-2121
[6]
Schmid P(2020)Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 21 44-59
[7]
Pfirschke C(2016)Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy Immunity 44 343-354
[8]
Kroemer G(2015)Natural and therapy-induced immunosurveillance in breast cancer Nat Med 21 1128-1138
[9]
Bezu L(2015)Combinatorial strategies for the induction of immunogenic cell death Front Immunol 6 187-1309
[10]
Sistigu A(2014)Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Nat Med 20 1301-1059